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Purpose/Objective: To compare the dosimetric results of 
intensity-modulated radiotherapy (IMRT) and volumetric 
modulated arc therapy (VMAT) and to assess the learning 
curve effect on dosimetric optimization in patients 
randomized in a prospective multicenter phase II trial of 
urethra-sparing stereotactic body radiotherapy (SBRT) for 
localized prostate cancer.  
Materials/Methods: Dosimetric data of the first 40 patients 
randomized between 07/2012 and 03/2014 in 9 different 
centers were analyzed. The SBRT protocol consisted of 36.25 
Gy in 5 fractions of 7.25 Gy to the planning target volume 
(PTV=prostate with (n=20) or without (n=20) seminal vesicles 
(SV) with a 5-mm anisotropic expansion, except 3-mm 
posteriorly). The prostatic urethra with an additional margin 
of 3 mm (urethral planning risk volume, uPRV) received 
simultaneously 5 x 6.5 Gy = 32.5 Gy. Plans were generated 
using either VMAT (n=20) or IMRT (n=20) technique, with 
each modality including (n=10) or not (n=10) SV in the PTV. 
All plans were optimized until the dose prescription 
parameters and organs at risk (OAR) dose-volume constraints 
were obtained. Mean doses (± SD) to the PTV, uPRV, and 
remaining OAR were analyzed. The PTV homogeneity index 
(HI) and the dice similarity coefficient (DSC) were also 
assessed. To evaluate the learning curve effect in VMAT 
optimization, VMAT plans of the first 20 patients were 
compared with VMAT plans generated in the last 20 
randomized patients (05/2014-08/2015).  
Results: Compared to IMRT plans, VMAT required a lower 
number of MU (2245 vs. 3685, p=.0001) and resulted in a 
better HI (0.90 vs. 0.11, p=.002) and uPRV coverage (D98% 
31.2 vs. 30.1 Gy, p=.001). Regardless of the RT technique, 
dose constraints were respected for all OAR. The V100, V90 and 
V80 for the rectal wall were 1.6±1.4% vs. 2.5±1.9% (ref. <5%), 
10.3±3.0% vs. 11.0±3.3% (ref. <10-15%) and 16.2±3.7% vs. 
14.8±4.2 (ref. <20-25%) for IMRT and VMAT patients, 
respectively, with no significant differences between the two 
techniques. For the bladder wall, the V100 and V90 were 
similar for IMRT and VMAT (7.8±3.7% vs. 7.0±3.8%, ref. <10-
15% and 15.3±4.0% vs. 13.1±4.8%, ref. <20%), while VMAT 
performed better than IMRT for the V50 (28.4±11.6% vs. 
37.2±9.2% (ref. <50%), p=.011). Compared to the first VMAT 
optimizations, plans generated in the last part of the study 
showed a better PTV DSC value (0.88 vs 0.78, p=.009), a 
reduced V100 (1.3 vs. 2.5%, p=.023) for the rectal wall, and an 
overall better bladder sparing (V100, V90 and V80, p<.05). 
Conclusions: For all participating centers, urethra-sparing 
SBRT plans met all the dosimetric endpoints in terms of PTV 
coverage as well as OAR sparing, irrespectively of the 
technique used. Compared with IMRT, VMAT plans resulted in 
more homogeneous dose distribution, reduced number of MU, 
and better uPRV coverage. Conformality and OAR sparing 
with VMAT may be improved after gaining experience in SBRT 
plan optimization.   
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